Roger Tung, Concert Pharmaceuticals CEO
Positive PhIII results in hand, Concert Pharma forges ahead with NDA and commercialization plans for hair loss drug
Concert Pharmaceuticals has been waiting to tout Phase III data amidst a sell-off of the bulk of its pipeline to Terran Biosciences and several …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
